If your child has Duchenne or Becker muscular dystrophy, cardiomyopathy isn't a risk you're trying to prevent. It's a progression you're tracking and managing from diagnosis forward.

Cardiovascular disease is the leading cause of death in Duchenne muscular dystrophy. Nearly every person with DMD will develop cardiomyopathy by adulthood. The cardiac muscle weakens for the same reason skeletal muscle does: the absence or malfunction of dystrophin, a protein that stabilizes muscle cell membranes during contraction. Without it, repeated contraction damages cells. In the heart, that damage is cumulative and irreversible.

The monitoring protocol exists because early detection buys time. Heart medications started before imaging shows damage can preserve function for years. This isn't about catching a disease that might develop. It's about tracking a disease that will, and intervening while the muscle is still working.

Why the Heart Is Affected

Dystrophin stabilizes muscle cells during contraction. The heart contracts about 100,000 times per day. Without dystrophin, each contraction causes microscopic tears in cardiac muscle cells. Over years, the muscle scars and stiffens. The heart enlarges to compensate, but eventually it can't pump efficiently.

In DMD, this process is inevitable. The genetic mutation eliminates functional dystrophin entirely. In Becker muscular dystrophy, some dystrophin is produced, so cardiac disease progresses more slowly and variably, but it still develops in most cases.

The timing varies. Some children show early signs of left ventricular dysfunction by age 10. Others maintain normal heart function into their late teens. Steroids slow skeletal muscle decline and appear to delay cardiac involvement, but they don't stop it.

The Monitoring Schedule

Cardiac monitoring starts at diagnosis or by age 6, whichever comes first. Here's the standard protocol.

Yearly from diagnosis:

• Electrocardiogram (ECG) to track electrical conduction
• Echocardiogram or cardiac MRI to measure heart size, wall thickness, and ejection fraction

What the tests measure:

• Ejection fraction is the percentage of blood the left ventricle pumps out with each beat. Normal is 55% or higher. Mild dysfunction starts around 50%. Moderate is 40-49%. Severe is under 40%.
• Wall motion abnormalities show which sections of the heart muscle are weakening first.
• Electrical conduction problems can appear before structural changes, signaling early disease.

Why cardiac MRI is preferred when possible:

Echocardiograms are faster and don't require sedation, but they're operator-dependent and can miss early dysfunction. Cardiac MRI provides higher resolution imaging and can detect fibrosis, scar tissue in the heart muscle, before function declines. If your cardiology team recommends MRI over echo, that's why.

Insurance often covers cardiac MRI for muscular dystrophy patients because it's considered medically necessary for disease monitoring. If pre-authorization is denied, your cardiologist can submit documentation that MRI is the standard of care for tracking DMD cardiac involvement.

When Medications Start

Heart medications typically start by age 10, even if test results are normal.

This isn't a precaution. It's treatment. Cardiomyopathy in DMD operates at the cellular level before it shows up on imaging. By the time ejection fraction drops or the heart enlarges on an echo, significant muscle damage has already occurred. Starting ACE inhibitors or beta blockers earlier protects the remaining healthy muscle from progressive strain.

The two main drug classes:

ACE inhibitors reduce the workload on the heart by lowering blood pressure and decreasing the resistance the heart pumps against. This slows the progression of ventricular dysfunction. Beta blockers reduce heart rate and the force of contraction, which decreases oxygen demand and mechanical stress on damaged muscle cells.

Some cardiologists start both at age 10. Others phase them in based on test results. Either approach is evidence-based. The key is starting treatment before ejection fraction declines, not waiting until dysfunction is measurable.

Side effects are generally mild: dizziness, fatigue, or low blood pressure during the first few weeks as the body adjusts. Dose adjustments usually resolve these. The long-term benefit of preserving heart function outweighs the temporary discomfort of starting medication.

What You're Watching For

Between scheduled cardiology visits, certain symptoms warrant immediate evaluation.

Call your cardiologist if your child develops:

• Persistent fatigue that's new or worsening, especially if they're tired after minimal activity
• Shortness of breath at rest or with mild exertion
• Swelling in the feet, ankles, or abdomen
• Rapid or irregular heartbeat, especially if sustained
• Chest pain or discomfort, even if rare in children

These symptoms can signal worsening heart failure or arrhythmia. They don't always mean an emergency, but they do mean the treatment plan needs adjustment.

Female Carriers Need Screening Too

Between 30% and 50% of women who carry a DMD mutation develop cardiac symptoms by middle age, even though they don't have muscular dystrophy themselves. They have one working copy of the dystrophin gene and one mutated copy. In most cells, the working copy compensates. In some cardiac cells, random X-inactivation silences the working copy, leaving those cells without functional dystrophin.

Over decades, the patchwork of affected cells can lead to dilated cardiomyopathy.

Screening recommendations for carriers:

• Baseline echocardiogram or cardiac MRI in late adolescence or early adulthood
• Repeat imaging every 3-5 years, or sooner if symptoms develop
• Earlier and more frequent monitoring if there's a family history of carrier cardiomyopathy

Mothers, sisters, and maternal aunts of boys with DMD should be evaluated. The same cardiac medications used for DMD patients are effective for symptomatic carriers. Early detection allows for treatment before significant dysfunction develops.

How the Disease Progresses

Cardiac function typically remains stable through childhood if monitoring and medications are in place. Decline usually becomes apparent in the late teens or twenties.

Stages of progression:

Early dysfunction shows as subtle decreases in ejection fraction or isolated wall motion abnormalities on imaging. Symptoms are minimal or absent. Medication adjustments can stabilize function at this stage for several years.

Moderate dysfunction means ejection fraction has dropped into the 40-49% range. Fatigue becomes noticeable. Additional medications, like aldosterone antagonists or diuretics, are added to reduce fluid retention and further decrease cardiac workload.

Advanced heart failure occurs when ejection fraction falls below 40%. At this stage, symptoms are significant. Walking across a room can cause shortness of breath. Fluid builds up in the lungs and legs. Treatment includes higher doses of existing medications, consideration of devices like implantable defibrillators to manage arrhythmias, and in some cases, discussion of heart transplant evaluation.

Not every patient follows this timeline. Some maintain stable function into their thirties with aggressive medical management. Others progress faster despite optimal treatment. The variability is partly genetic, as some DMD mutations are associated with more severe cardiac involvement, and partly dependent on how early monitoring and treatment began.

What to Ask Your Cardiology Team

You don't need to be a cardiologist to participate meaningfully in your child's care. These questions help you understand what the tests are showing and what changes to expect.

"What's the current ejection fraction, and how does it compare to last year?" "Are there any new wall motion abnormalities or conduction changes?" "When should we consider adding or adjusting medications?" "At what point would we discuss device placement, like an ICD?" "How often should we schedule follow-ups given the current findings?"

Cardiologists managing DMD patients expect these questions. Your child's cardiac care is a long-term relationship built on consistent monitoring and proactive adjustment. The more you understand the metrics they're tracking, the more useful those annual visits become.

Managing Expectations Without Catastrophizing

Cardiomyopathy in DMD is serious. It's also manageable for years, sometimes decades, with the right protocol.

The monitoring schedule exists because intervention works. Medications started early preserve function. Regular imaging catches changes before they become crises.

You're tracking a known progression and adjusting treatment to slow it. That distinction matters. The anxiety doesn't disappear, but the actions you can take are concrete and evidence-based.

The same care and planning you bring to mobility aids, respiratory support, and school accommodations applies here. Cardiac monitoring is part of the comprehensive management plan, not a separate disaster waiting to happen.

Where to Find Specialized Care

Pediatric cardiologists with neuromuscular disease expertise understand the DMD cardiac timeline and tailor treatment accordingly. If your child's current cardiologist isn't familiar with muscular dystrophy protocols, ask for a referral to a center with a neuromuscular clinic.

Large academic medical centers and children's hospitals often have multidisciplinary DMD clinics where neurology, cardiology, pulmonology, and orthopedics coordinate care. That model reduces the burden of managing multiple specialists separately and ensures cardiac monitoring doesn't fall through the cracks.

If travel to a specialized center isn't feasible for every visit, many DMD cardiology teams will consult with local providers to ensure your child's care follows current guidelines. The initial evaluation and treatment plan can happen at the specialty center, with routine monitoring handled locally and results reviewed remotely.

Cardiac care for muscular dystrophy is a long game. The protocol is established, the medications are effective, and early monitoring gives you the time and information you need to make decisions as the disease progresses. That's not reassurance. It's logistics. And logistics, you can manage.